Overview

Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
An open-label, single dose pharmacokinetic study of Xyntha (Moroctocog Alfa (AF-CC), Recombinant Factor VIII) in male Chinese subjects with hemophilia A
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Factor VIII